KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Current Leases (2019 - 2025)

West Pharmaceutical Services' Current Leases history spans 7 years, with the latest figure at $22.7 million for Q4 2025.

  • For Q4 2025, Current Leases rose 26.82% year-over-year to $22.7 million; the TTM value through Dec 2025 reached $22.7 million, up 26.82%, while the annual FY2025 figure was $22.7 million, 26.82% up from the prior year.
  • Current Leases for Q4 2025 was $22.7 million at West Pharmaceutical Services, up from $21.4 million in the prior quarter.
  • Across five years, Current Leases topped out at $22.7 million in Q4 2025 and bottomed at $8.1 million in Q3 2021.
  • The 5-year median for Current Leases is $16.3 million (2023), against an average of $15.8 million.
  • The largest annual shift saw Current Leases fell 18.18% in 2021 before it surged 72.04% in 2022.
  • A 5-year view of Current Leases shows it stood at $9.3 million in 2021, then soared by 72.04% to $16.0 million in 2022, then grew by 10.62% to $17.7 million in 2023, then increased by 1.13% to $17.9 million in 2024, then grew by 26.82% to $22.7 million in 2025.
  • Per Business Quant, the three most recent readings for WST's Current Leases are $22.7 million (Q4 2025), $21.4 million (Q3 2025), and $20.9 million (Q2 2025).